Abstract Background The beneficial role of patient education (PE) is well established in chronic diseases and has been demonstrated in Inflammatory Bowel Diseases (IBD) by the ECIPE study (1). Seven years ago, the first national survey on PE programme in IBD centres led to the publication of a white paper containing fifteen recommendations (2). This survey showed that: less than one third centres had obtained official approval for PE; the number of nurses officially recognized in their educational roles was still very low (n = 60); patients were not involved in PE programmes. The aim of this new survey was to measure the evolution of PE programmes in IBD centres in France. Methods From April to May 2025, the 57 active centres in PE for IBD were contacted. A questionnaire including 38 questions was developed by a committee of physicians, PE specialists and patients. The questionnaire was distributed and the responses were collected electronically. The questions focused on: 1) the number and size of the centres involved; 2) the place of PE in the care pathway; 3) official recognition of PE; 4) the number and type of staff trained in PE; 5) the place and role of the expert patient; 6) the main topics covered in workshops; 7) funding and promotion. Results Fifty of the 57 centres (87,7%) responded to the questionnaires. 1) The number of active approved centres has risen from 10 to at least 50, including many medium-sized hospitals. 2) The number of full or part-time nurses specialized in PE has risen from 60 to 323. 3) The presence of expert patient in the centres has risen from 0 to 60%, giving them a decisive role in the workshops. 4) The topics covered in the workshops are more numerous and are described in the survey. 5) For more than 50% (26% in 2019) of teams PE has become a priority in their centre. 6) A systematic evaluation during the workshop debriefing shows that more than 90% of participants were satisfied. Three negative points emerge from the survey: 1) insufficient long-term funding and low evaluation on this activity for half of the centres; 2) still insufficient number of expert patients integrated into the teams; 3) low development of PE programmes in private practice. Finally, among the fifteen proposals in the 2019 white paper, ten have significantly progressed. Conclusion PE in IBD patients, has made considerable progress in recent years, not only in large IBD centres. The results suggest that, in France, several thousand patients have improved their QoL thanks PE. However PE needs to be better promoted. The integration of expert patients should be systematised and PE in private practice warrants further development. Ultimately, we believe that a European survey should be initiated. References: (1) Moreau J, et al. J Crohns Colitis 202;15:432-40 (2) L’ETP-MICI : Quels défis 10 ans après la loi HPST ? KPL édition-Mars 2019. Conflict of interest: Moreau, Jacques: No conflict of interest Devos, Corinne: No conflict of interest Nion-Larmurier, Isabelle: Takeda, J & J, Nestle health sciences Allez, Matthieu: Abbvie, Amgen, Astra-Zeneca, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Galapagos, Genentech, Gilead, IQVIA, Janssen, Novartis, Pfizer, Spyre therapeutics, Roche, Takeda, Tillots Martinez Vinson, Christine: AbbVie, MSD, Nestle, Biogen Monboussin, Sylvie: No conflict of interest Delrieu, Violette: No conflict of interest Baudry Schraub, Clotilde: Abbvie, Amgen, Celltrion, Takeda Hebuterne, Xavier: Xavier Hébuterne reports clinical research funding from AbbVie, Abivax, Alphasigma, Arena Pharmaceuticals, Celgene, Eli Lilly, Enterome, Gilead, Janssen, InDex Pharmaceuticals, Pfizer, Roche, Salix, Sangamo, Takeda, Theravance, serving on advisory boards for AbbVie, Abivax, Arena Pharmaceuticals, Gilead, Janssen, Pfizer, Roche, Takeda, and participating in lectures and educational activities for AbbVie, Amgen, Baxter, Fresenius Kabi, Janssen, MSD, Mylan, Nutricia, Pfizer, Tillots, and Takeda. Noë, Christine: No conflict of interest
Moreau et al. (Thu,) studied this question.